<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical uses of sotalol
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical uses of sotalol
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical uses of sotalol
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elsa-Grace Giardina, MD, MS, FACC, FACP, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rod Passman, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark S Link, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hugh Calkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 14, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         , a methanesulfonanilide, is a class III antiarrhythmic drug  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 1
         </a>
         ) that is used for the treatment of both atrial and ventricular arrhythmias. Sotalol was originally approved by the FDA (tradename Betapace) for the treatment of life-threatening ventricular arrhythmias. The present commercial product (tradename Betapace AF) is intended for use in atrial fibrillation (AF), with the caveat that sotalol is not effective for conversion of AF to sinus rhythm, but it may be used to prevent AF. Although both commercial presentations contain sotalol, Betapace should not be substituted for Betapace AF because of significant differences in the labeling sections on indications, dosing, administration, and safety profile. Additionally, an injectable form of sotalol was approved by the FDA in July 2009. The package inserts for Betapace and Betapace AF contain black box warnings regarding potential for QT prolongation and ventricular arrhythmias [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Cardiac toxicity'
         </a>
         below.)
        </p>
        <p>
         This topic will review the electrophysiology and mechanisms of action of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , and will discuss dosing, the different settings in which sotalol has been used as an antiarrhythmic drug, and major side effects. Recommendations for the role of sotalol in the treatment of atrial and ventricular arrhythmias are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/972.html" rel="external">
          "Pharmacologic therapy in survivors of sudden cardiac arrest", section on 'Choice of pharmacologic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ELECTROPHYSIOLOGY AND MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         consists of a racemic mixture of d and l isomers in an approximate ratio of 1:1; this mixture is often called dl-sotalol. D- and l-stereoisomers of sotalol have been studied individually, but only dl-sotalol is commercially available. The two isomers contribute to the unique antiarrhythmic properties of sotalol [
         <a href="#rid2">
          2-5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The d isomer prolongs repolarization by blocking IKr  (
         <a class="graphic graphic_figure graphicRef70771" href="/z/d/graphic/70771.html" rel="external">
          figure 1
         </a>
         ), the rapid component of the delayed rectifier potassium current that is responsible for phase 3 repolarization of the action potential  (
         <a class="graphic graphic_figure graphicRef71390" href="/z/d/graphic/71390.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid6">
          6,7
         </a>
         ]. This represents a class III effect. (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The l isomer has two actions: it prolongs repolarization and it has beta blocking activity. The beta blocker effect is dose-dependent, is not cardioselective, and is not associated with membrane stabilizing activity or intrinsic sympathomimetic activity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Class III activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antiarrhythmic activity of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is primarily mediated by its class III property  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 1
         </a>
         ), which results in prolongation of the monophasic action potential duration as well as lengthening of the effective refractory period (ERP) in the atria, atrioventricular (AV) node (as reflected by the AH interval), ventricles, and antegrade and retrograde bypass tracts (when present) [
         <a href="#rid4">
          4,8-10
         </a>
         ]. The class III effect results from blockade of the rapid component of the delayed rectifier potassium current (IKr) that is responsible for phase 3 repolarization of the action potential  (
         <a class="graphic graphic_figure graphicRef71390" href="/z/d/graphic/71390.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid6">
          6,7
         </a>
         ].The prolongation of cardiac action potential duration does not appear to be related to concurrent beta blockade, since d-sotalol, which has little beta blocking activity, produces a similar delay in repolarization as l-sotalol [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The effect of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         on the action potential duration shows
         <strong>
          reverse use dependence
         </strong>
         , which is seen with other class III antiarrhythmic drugs except for
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval [
         <a href="#rid11">
          11
         </a>
         ]. As a result, the QT interval is prolonged as the heart rate slows, which could explain the association between bradycardia and antiarrhythmic drug-induced torsades de pointes and the possible decrease in drug efficacy at higher heart rates. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Pathophysiology'
         </a>
         and
         <a class="local">
          'Proarrhythmia'
         </a>
         below.)
        </p>
        <p>
         The clinical manifestations of sotalol-induced beta blockade include an increased sinus cycle length (slowed heart rate), decreased AV nodal conduction and increased AV nodal refractoriness (prolonged PR interval) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Effects on the ECG
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combined actions of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         produce a variety of changes in the electrocardiogram (ECG) [
         <a href="#rid4">
          4,12,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because of its beta blocking activity,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         slows the sinus rate by approximately 25 percent and slightly prolongs the PR interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The QRS duration is not altered, since ventricular conduction at normal sinus rates is unchanged [
         <a href="#rid12">
          12,13
         </a>
         ]. This is thought to reflect a lack of effect of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         on the His-Purkinje (HV) interval [
         <a href="#rid4">
          4,9,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The QT interval is prolonged in a dose-dependent fashion [
         <a href="#rid15">
          15
         </a>
         ]. Since the QRS duration is not prolonged, the increase in QT interval results solely from delayed repolarization (ie, the JT interval) [
         <a href="#rid12">
          12,13
         </a>
         ]. In a review of 114 patients given chronic oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         therapy, the average increase in QT interval was 80 and 91 msec with 320 and 640 mg/day [
         <a href="#rid12">
          12
         </a>
         ]. However, the increase in QTc, which is corrected for heart rate, was less prominent (21 and 30 msec, respectively). (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis", section on 'QT rate correction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3982161750">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is, essentially, completely absorbed and not metabolized. Consequently, bioavailability is close to 100 percent. Age and food have slight but unimportant effects on bioavailability. The maximum concentration of sotalol is achieved within 2 to 3 hours with a half-life between 7 and 15 hours. Excretion of sotalol is primarily through the kidneys, with no metabolism by liver and no first-pass effect. Therefore, sotalol plasma levels and half-life are directly related to creatinine clearance and glomerular filtration rate. Appropriate dose adjustments must be made for patients with impaired renal function or increased renal blood flow, as in pregnancy. The beta-adrenoceptor antagonistic effects of sotalol are directly related to plasma levels, which, in turn, are directly related to dose. However, the beta-adrenoceptor antagonism half-life is longer than the sotalol plasma half-life [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          DOSING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dose of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         should be individualized on the basis of therapeutic response and tolerance. Because of its beta blocking activity, sotalol should not be used in patients with uncontrolled asthma, sinus bradycardia, Mobitz II second degree AV block or third degree AV block (unless the patient is treated with a pacemaker), cardiogenic shock, or uncontrolled heart failure [
         <a href="#rid5">
          5
         </a>
         ]. In addition, because sotalol prolongs the QT interval, it should not be used in patients with congenital or acquired long QT syndrome, and should be used with caution in patients taking other medications known to prolong the QT interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Proarrhythmia'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H286407628">
         <span class="h2">
          Initiation of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bradycardic and proarrhythmic events can occur after the initiation of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         therapy and with each upward dosing adjustment [
         <a href="#rid17">
          17,18
         </a>
         ]. As a result, sotalol should be initiated in a hospital with facilities for cardiac rhythm monitoring and assessment. The package insert for sotalol contains a black box warning regarding initiation of the drug in a center with QT monitoring and cardiac resuscitation capabilities. However, some providers have initiated sotalol (or uptitrated doses) in an off-label manner in the outpatient setting in patients felt to be at low risk of QT prolongation or polymorphic VT. Before beginning sotalol, previous antiarrhythmic therapy should be withdrawn under careful monitoring for a minimum of two to three half-lives, if clinically possible. (See
         <a class="local">
          'Proarrhythmia'
         </a>
         below.)
        </p>
        <p>
         The recommended initial dose of oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         in adults is 80 mg twice daily whether used for the treatment of ventricular arrhythmias or atrial fibrillation. If necessary, the initial dose can be increased gradually to a maximum daily of 240 mg or 320 mg. Dose adjustments should be made at three day intervals so that steady-state plasma concentrations can be attained and the QT interval monitored. In a retrospective analysis, this standard approach was compared with initiating sotalol at 120 to 160 mg orally twice per day [
         <a href="#rid19">
          19
         </a>
         ]. The accelerated dosing regimen neither shortened hospitalization nor had any effect on treatment efficacy. Due to the marginally increased risk of cardiac and non-cardiac side effects with an accelerated regimen, we favor the traditional starting dose of 80 mg twice daily.
        </p>
        <p>
         As of March 2020, intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         has an updated FDA-approved dosing regimen for in-hospital initiation and reinitiation of patients on sotalol therapy. The key change is that with the use of intravenous sotalol, patients can now be initiated (titrated to steady-state blood levels) on sotalol therapy in the hospital in one day (versus three days). In addition, with intravenous sotalol (unlike with oral sotalol), patients can be initiated at
         <strong>
          either
         </strong>
         80
         <strong>
          or
         </strong>
         120 mg. In other words, with intravenous sotalol, patients may be initiated at 120 mg without titrating up from 80 mg.
        </p>
        <p class="headingAnchor" id="H3231243742">
         <span class="h2">
          Dose adjustment with chronic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is primarily excreted unchanged in the urine, since it is not appreciably metabolized in the liver [
         <a href="#rid3">
          3
         </a>
         ]. As a result, the elimination half-life is prolonged in patients with renal insufficiency. When sotalol is given for the treatment of ventricular arrhythmias, the dosing interval should be modified based upon the reduction in creatinine clearance:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &gt;60 mL/min – 12 hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         30 to 60 mL/min – 24 hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         10 to 29 mL/min – 36 to 48 hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         &lt;10 mL/min – should be individualized
        </p>
        <p>
        </p>
        <p>
         Patients with severe renal disease are at risk for potentially life-threatening ventricular arrhythmia even if low doses are used [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
         When used for the treatment of atrial fibrillation,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is considered contraindicated when the creatinine clearance is less than 40 mL/min.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Intravenous sotalol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         has primarily been used to terminate supraventricular tachyarrhythmias [
         <a href="#rid22">
          22-24
         </a>
         ]. It has also been used to terminate spontaneous sustained ventricular tachycardia (VT) and to suppress inducible ventricular tachyarrhythmia during electrophysiology study [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
         Several reports have described the value and limitations of intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         to convert arial fibrillation to sinus rhythm.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A review concerning the effectiveness of antiarrhythmic drugs administered intravenously indicates that
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         has a modest success on cardioversion of AF to sinus rhythm approximating 30 percent; it is less effective than class I agents or
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         [
         <a href="#rid27">
          27
         </a>
         ]. In particular, high-dose ibutilide showed a greater conversion rate than intravenous sotalol [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis concluded that intravenous and oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         for conversion of AF of varied duration are as effective as class IA or class IC agents, and as effective as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         for pharmacological conversion of AF [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another report found
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         less efficient than
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         , or
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         and likely as effective as intravenous
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A prospective study from Australia compared intravenous administration of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         [
         <a href="#rid30">
          30
         </a>
         ]. The results at 24 hours revealed conversion to sinus rhythm was 50 percent for digoxin, 69 percent for amiodarone, and 80 percent for sotalol. In addition, the conversion at 48 hours was 58 percent for digoxin, 77 percent for amiodarone, and 88 percent for sotalol.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3800783813">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         loading dose is complete, generally the patient is asked to return for an electrocardiogram (ECG) within one and two weeks, looking for QT interval prolongation and bradyarrhythmia. Patients should typically have an ECG performed every six months while taking sotalol, and whenever any additional QT prolonging medications are newly prescribed. Routine laboratory studies are not needed to monitor sotalol levels or for potential toxicities.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          CLINICAL INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is used for the treatment of documented ventricular arrhythmias (ie, sustained ventricular tachycardia [VT]) that, in the judgment of the clinician are life-threatening, and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation (AF) and atrial flutter who are currently in sinus rhythm.
        </p>
        <p>
         What follows is a brief review of the major settings in which
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is given with links to the topic reviews in which the role of sotalol therapy is discussed in detail.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Ventricular arrhythmias
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is used to prevent recurrence of sustained VT or ventricular fibrillation (VF) [
         <a href="#rid12">
          12,31-33
         </a>
         ]. The main setting in which sotalol is used for VT/VF is as adjunctive therapy to an ICD to reduce the frequency of appropriate shocks or of inappropriate shocks due to supraventricular arrhythmias. However, sotalol may be used as primary therapy in patients who do not want or are not candidates for an ICD (eg, due to marked comorbidities or end-stage heart failure that make death likely). Although sotalol reduces both recurrent arrhythmia and the frequency of ICD shocks [
         <a href="#rid34">
          34
         </a>
         ], sotalol is typically second-line therapy to empiric
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy", section on 'Antiarrhythmic drugs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/972.html" rel="external">
          "Pharmacologic therapy in survivors of sudden cardiac arrest", section on 'Choice of pharmacologic therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is effective in patients with arrhythmogenic right ventricular cardiomyopathy who have either inducible or noninducible non-life-threatening VT; in contrast, other antiarrhythmic drugs have little efficacy [
         <a href="#rid35">
          35
         </a>
         ]. Thus, initial therapy with sotalol is a reasonable option for many such patients. For those that do not respond to sotalol, response to other drugs is unlikely, and consideration should be given to nonpharmacologic therapy such as radiofrequency catheter ablation. (See
         <a class="medical medical_review" href="/z/d/html/4932.html" rel="external">
          "Arrhythmogenic right ventricular cardiomyopathy: Treatment and prognosis", section on 'Antiarrhythmic drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A preparation containing only the d isomer has been developed as a "pure" class III drug [
         <a href="#rid36">
          36,37
         </a>
         ]. However, in the Survival with Oral D-sotalol (SWORD) trial of patients with a reduced left ventricular ejection fraction and either a recent myocardial infarction (MI) or symptomatic heart failure and a remote MI, d-sotalol therapy, compared with placebo, was associated with a significant
         <strong>
          increase in
         </strong>
         mortality that was largely due to an increase in presumed arrhythmic deaths [
         <a href="#rid37">
          37
         </a>
         ]. This observation suggests an important contribution from the beta blocking activity that is seen with dl-sotalol.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Atrial arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both the class III and beta blocking activity of dl-sotalol contribute to its use in the treatment of atrial arrhythmias, mostly atrial fibrillation (AF).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         promotes maintenance of sinus rhythm after cardioversion in patients with AF. The main indication for sotalol, if a rhythm control strategy is chosen, is in patients with underlying coronary heart disease  (
         <a class="graphic graphic_algorithm graphicRef95079" href="/z/d/graphic/95079.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In comparison, oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         has limited efficacy for pharmacologic cardioversion of AF to sinus rhythm [
         <a href="#rid38">
          38
         </a>
         ] and, where available, intravenous sotalol is less effective than other drugs [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">
          "Atrial fibrillation: Cardioversion", section on 'Pharmacologic cardioversion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         appears to be effective for the prevention of AF after cardiac surgery (eg, coronary artery bypass graft or valve surgery) [
         <a href="#rid39">
          39
         </a>
         ]. In a meta-analysis of 15 studies involving sotalol for the prevention of AF after cardiac surgery, sotalol was significantly more effective in preventing AF than no treatment, placebo, or beta blockers, and it was equally as effective as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. Recommendations about the choice of a particular agent for the prevention of AF after cardiac surgery are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/1011.html" rel="external">
          "Atrial fibrillation and flutter after cardiac surgery"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The safety of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         was compared with
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         after AF ablation. Propensity-score matching resulted in 1815 patients receiving dronedarone matched 1:1 to patients receiving sotalol. Patients on dronedarone had lower risk of cardiovascular hospitalization compared with patients treated with sotalol, predominantly attributable to lower rates of ATA-related hospitalization. In addition, dronedarone-treated patients had a better safety profile after ablation compared with sotalol patients because of lower rates of combined proarrhythmia, predominantly driven by lower rates of bradycardic proarrhythmia and need for pacemaker implantation [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The DASH-AF study compared the safety and feasibility of intravenous
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         compared with the traditional five-dose inpatient titration of oral sotalol for the treatment of atrial arrhythmias. The nonrandomized study compared QT interval changes, safety outcomes, and cost in 120 patients receiving inpatient oral loading with 120 patients receiving intravenous sotalol at a loading dose of 125 mg for all patients with a CrCL &gt;60 m/min for an intended maintenance regimen of 120 mg twice daily and 82.5 mg for CrCL &gt;60 mL/min for an intended maintenance dose of 80 mg twice daily; oral sotalol was started four hours after the intravenous sotalol infusion. The majority (60 percent) of oral loading was at the 120 mg twice-daily dose. Patients were matched on AF type and CrCL. There was no significant change in QTc in both groups, and the risk of adverse events was also similar. The estimated cost savings with intravenous sotalol was $3,500.68 per admission.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          Fetal arrhythmias
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal tachycardia is a serious condition for which treatment should be initiated, especially in the presence of hydrops fetalis. The management of fetal arrhythmias is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          MAJOR SIDE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is generally well tolerated. It has been estimated that sotalol is discontinued because of side effects in approximately 15 percent of patients [
         <a href="#rid4">
          4,42
         </a>
         ]. The major causes for cessation of therapy are fatigue (4 percent), bradycardia, dyspnea, proarrhythmia (each 3 percent), and dizziness and asthenia (each 2 percent) [
         <a href="#rid4">
          4
         </a>
         ]. However, some of these side effects, such as dizziness, fatigue, and anxiety, may not be more common than with placebo [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         The potential for cardiac toxicity is clearly of greatest concern. Bradycardic and proarrhythmic events can occur after the initiation of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See
         <a class="local">
          'Initiation of therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Cardiac toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The two major cardiac side effects of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         are proarrhythmia, most often torsades de pointes, and bradycardia. In addition, the beta blocking activity of sotalol can cause new or worsened heart failure.
        </p>
        <p>
         The arrhythmic and bradycardic complications often occur within the first three days after the initiation of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         therapy and with each upward dosing adjustment [
         <a href="#rid17">
          17,18
         </a>
         ]. As a result, sotalol should generally be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See
         <a class="local">
          'Initiation of therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Proarrhythmia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         , like other class III drugs, has the potential to be arrhythmogenic due to marked prolongation of the duration of the action potential that is manifested on the surface electrocardiogram (ECG) by prolongation of the QT interval [
         <a href="#rid3">
          3,43
         </a>
         ]. This effect is mediated by blockade of IKr  (
         <a class="graphic graphic_figure graphicRef70771" href="/z/d/graphic/70771.html" rel="external">
          figure 1
         </a>
         ), the rapid component of the delayed rectifier potassium current that is responsible for phase 3 repolarization of the action potential  (
         <a class="graphic graphic_figure graphicRef71390" href="/z/d/graphic/71390.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid6">
          6,7
         </a>
         ]. (See
         <a class="local">
          'Class III activity'
         </a>
         above.)
        </p>
        <p>
         At standard doses between 160 and 320 mg/day,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         increases by QT interval by 40 to 100 msec [
         <a href="#rid3">
          3
         </a>
         ]. However, the amount of change in the QT interval is highly variable and difficult to predict in an individual patient. In a cohort of 541 patients starting sotalol, the average change in corrected QT interval (QTc using the Bazett formula) was 3±42 milliseconds at two hours and 11±37 milliseconds at 48 hours following the initial dose [
         <a href="#rid44">
          44
         </a>
         ]. The maximum recommended QTc interval on sotalol is 500 to 520 msec [
         <a href="#rid3">
          3,4,45
         </a>
         ].
        </p>
        <p>
         The effect of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         on the action potential duration shows
         <strong>
          reverse use dependence
         </strong>
         , which is seen with other class III antiarrhythmic drugs except for
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval [
         <a href="#rid11">
          11
         </a>
         ]. As a result, the QT interval is prolonged as the heart rate slows, which could explain the association between bradycardia and antiarrhythmic drug-induced torsades de pointes. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Pathophysiology'
         </a>
         .)
        </p>
        <p>
         The most important clinical manifestation of sotalol-induced proarrhythmia is torsades de pointes, characterized by a "twisting" of the peaks of the QRS complexes around the isoelectric line of the ECG  (
         <a class="graphic graphic_waveform graphicRef53891" href="/z/d/graphic/53891.html" rel="external">
          waveform 1
         </a>
         ). Triggered activity caused by early afterdepolarizations is thought to be responsible for the induction of this arrhythmia, which is most likely to occur in patients with prolongation of the QT interval.
        </p>
        <p>
         The reported risk of torsades de pointes has varied from 1 to 4 percent [
         <a href="#rid34">
          34,42,46
         </a>
         ]. The incidence of and risk factors for torsades de pointes were described in a 1996 review of 3135 patients who were treated with
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         for sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (41 percent) or non-life-threatening arrhythmias such as ventricular premature beats, atrial fibrillation (AF), nonsustained VT, or paroxysmal supraventricular tachycardia (59 percent) [
         <a href="#rid46">
          46
         </a>
         ]. The overall rate of torsades de pointes was 2.5 percent at a median follow-up of 164 days. However, a number of groups at significantly increased risk were identified:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         dose above 320 mg/day (3.7 versus 1.8 and 0.1 percent at doses of 161 to 320 mg/day and ≤160 mg/day, respectively).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum creatinine above 1.4 mg/dL [124 micromol/L] in women and 1.6 mg/dL [141 micromol/L] in men (5.1 versus 2.2 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sustained VT/VT as the presenting arrhythmia (4.5 versus 1.1 percent with other arrhythmias such as atrial fibrillation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of heart failure (5.0 versus 1.7 percent without heart failure) or coronary heart disease (3.1 versus 1.9 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female gender (4.1 versus 1.9 percent in men). The gender difference was independent of dose-related bradycardic responses and was similar in women greater than 50 and ≤50 years of age, which suggests that estrogen may not be responsible for the increased risk in women.
        </p>
        <p>
        </p>
        <p>
         An increase in risk in females has also been noted with torsades de pointes due to other antiarrhythmic drugs, noncardiac drugs, and the congenital long QT syndrome [
         <a href="#rid47">
          47-49
         </a>
         ]. In each of these settings, females constitute approximately 70 percent of affected patients. Compared with males, females have a longer corrected QT interval and a greater response to drugs that block IKr, potentiating the development of torsades de pointes [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Risk factors for drug-induced long QT syndrome'
         </a>
         .)
        </p>
        <p>
         There are also general predisposing factors such as bradycardia, which is thought to result from reverse use dependence in which the QT interval is prolonged as the heart rate slows, and other factors that prolong the baseline QT interval such as hypokalemia, hypomagnesemia, and the concomitant use of other drugs that prolong the QT interval, including antiarrhythmic drugs such as
         <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">
          procainamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         , and the other class III agents (
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          ibutilide
         </a>
         )  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ). All of these drugs predispose to torsades de pointes except for amiodarone. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse cardiac effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Bradycardia
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         has the potential to cause all of the rhythm effects induced by beta blockade, including sinus bradycardia and atrioventricular (AV) block. Bradyarrhythmias, mostly sinus bradycardia, occur in approximately 10 to 15 percent of patients [
         <a href="#rid3">
          3,4,17,18,34,42
         </a>
         ]. By comparison, sinus node arrest and second or third degree heart block occur in ≤1 percent [
         <a href="#rid4">
          4,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Heart failure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients treated with
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , particularly for ventricular arrhythmias, have underlying cardiac disease. Fortunately, impairment of myocardial contractility in patients treated with sotalol is less than might be expected with a beta blocker. Most patients have no significant decrease in left ventricular ejection fraction [
         <a href="#rid3">
          3
         </a>
         ], and it has been estimated that clinically significant heart failure aggravation occurs in only 1.5 to 3 percent of patients [
         <a href="#rid42">
          42,45,51
         </a>
         ]. The risk is greater in patients with a prior history of heart failure, particularly those with a baseline ejection fraction of &lt;30 percent [
         <a href="#rid4">
          4,5,42,46
         </a>
         ]. In the review of 3135 patients cited above, the incidence to torsades de pointes was much higher in patients with heart failure (5.0 versus 1.7 percent without heart failure) [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Because of the concern related to the safety of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         in patients with heart failure,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is generally preferred for the treatment of ventricular arrhythmias and for maintenance of sinus rhythm in atrial fibrillation when pharmacologic therapy is given. However, sotalol safely reduces the frequency of recurrent arrhythmia and appropriate shocks in patients with an implantable cardioverter-defibrillator (ICD) [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/946.html" rel="external">
          "Secondary prevention of sudden cardiac death in heart failure and cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/977.html" rel="external">
          "The management of atrial fibrillation in patients with heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         should not be used in patients with uncontrolled asthma, sinus bradycardia, Mobitz II second degree AV block and third degree AV block, congenital long QT syndrome, acquired long QT syndrome  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ), cardiogenic shock, or uncontrolled heart failure. In addition, it should be used with caution in patients with reduced renal function, since decreased clearance can result in drug accumulation and possible proarrhythmia [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1358169962">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115586.html" rel="external">
          "Society guideline links: Ventricular arrhythmias"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">
          "Society guideline links: Supraventricular arrhythmias"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10900382">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Introduction
         </strong>
         –
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         consists of a racemic mixture of d and l isomers in an approximate ratio of 1:1. The two isomers contribute to the unique antiarrhythmic properties of sotalol, with d isomer prolonging repolarization by blocking the rapid component of the delayed rectifier potassium current that is responsible for phase 3 repolarization of the action potential, while the l isomer both prolongs repolarization and has beta blocking activity. (See
         <a class="local">
          'Electrophysiology and mechanism of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism
         </strong>
         – The effect of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         on the action potential duration shows
         <strong>
          reverse use dependence
         </strong>
         , which is seen with other class III antiarrhythmic drugs, except for
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         . Reverse use dependence is defined as an inverse correlation between the heart rate and the QT interval. As a result, the QT interval is prolonged as the heart rate slows, with an associated risk of drug-induced torsades de pointes and a possible decrease in drug efficacy at higher heart rates. (See
         <a class="local">
          'Class III activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Bradycardic and proarrhythmic events occur in up to 20 percent of patients after the initiation of
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         therapy and with each upward dosing adjustment. As a result, sotalol should be initiated and doses increased in a hospital with facilities for cardiac rhythm monitoring and assessment. (See
         <a class="local">
          'Dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recommended initial dose of oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         in adults is 80 mg twice daily whether used for the treatment of ventricular arrhythmias or atrial fibrillation (AF). If necessary, the initial dose can be increased gradually to a total daily dose of 240 mg or 320 mg. Dose adjustments should be made at three day intervals so that steady-state plasma concentrations can be attained and the QT interval monitored. The dosing interval requires modification in patients with impaired renal function and reduced creatinine clearance. (See
         <a class="local">
          'Dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Proarrhythmia
         </strong>
         –
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         should
         <strong>
          not
         </strong>
         be given to patients with congenital or acquired long QT syndrome unless the cause can be reversed because of the risk of further QT interval prolongation and proarrhythmia, particularly torsades de pointes  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Proarrhythmia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical indications
         </strong>
         – Oral
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         is used for the treatment of ventricular arrhythmias (ie, sustained VT) that are potentially life-threatening and for the maintenance of normal sinus rhythm in patients with symptomatic atrial fibrillation and atrial flutter who are currently in sinus rhythm. (See
         <a class="local">
          'Clinical indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         is generally well tolerated, being discontinued because of side effects in approximately 15 percent of patients. The major causes for intolerance are fatigue, bradycardia, dyspnea, proarrhythmia, dizziness and asthenia. (See
         <a class="local">
          'Major side effects'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kato R, Ikeda N, Yabek SM, et al. Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 1986; 7:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohnloser SH, Woosley RL. Sotalol. N Engl J Med 1994; 331:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. Am Heart J 1999; 137:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN. Sotalol: Current Status and Expanding Indications. J Cardiovasc Pharmacol Ther 1999; 4:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Numaguchi H, Mullins FM, Johnson JP Jr, et al. Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res 2000; 87:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodsky M, Saini R, Bellinger R, et al. Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. Am Heart J 1994; 127:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nademanee K, Feld G, Hendrickson J, et al. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985; 72:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell LB, Wyse DG, Duff HJ. Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 1987; 76:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990; 81:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias. Am J Cardiol 1991; 67:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creamer JE, Nathan AW, Shennan A, Camm AJ. Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. Am J Cardiol 1986; 57:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touboul P, Atallah G, Kirkorian G, et al. Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties. Am Heart J 1984; 107:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang T, Bergstrand RH, Thompson KA, et al. Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol 1986; 57:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 1990; 65:12A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisel WH, Kuntz KM, Reimold SC, et al. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital. Ann Intern Med 1997; 127:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung MK, Schweikert RA, Wilkoff BL, et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998; 32:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim RJ, Juriansz GJ, Jones DR, et al. Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias. Pacing Clin Electrophysiol 2006; 29:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizza C, Valderrabano M, Singh BN. Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 1999; 4:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiffel JA, Appel G. Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy. J Cardiovasc Pharmacol Ther 2001; 6:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sung RJ, Tan HL, Karagounis L, et al. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group. Am Heart J 1995; 129:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vos MA, Golitsyn SR, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group. Heart 1998; 79:568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisinger J, Gatterer E, Heinze G, et al. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998; 81:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho DS, Zecchin RP, Richards DA, et al. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh BN, Kehoe R, Woosley RL, et al. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. Am Heart J 1995; 129:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lévy S. Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European perspective. J Cardiovasc Electrophysiol 2021; 32:3259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milan DJ, Saul JP, Somberg JC, Molnar J. Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiology 2017; 136:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kpaeyeh JA Jr, Wharton JM. Sotalol. Card Electrophysiol Clin 2016; 8:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph AP, Ward MR. A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. Ann Emerg Med 2000; 36:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM. Usefulness of sotalol for life-threatening ventricular arrhythmias. Am J Cardiol 1993; 72:51A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med 1993; 329:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haverkamp W, Martinez-Rubio A, Hief C, et al. Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. J Am Coll Cardiol 1997; 30:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacifico A, Hohnloser SH, Williams JH, et al. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group. N Engl J Med 1999; 340:1855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wichter T, Borggrefe M, Haverkamp W, et al. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation 1992; 86:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohnloser SH, Meinertz T, Stubbs P, et al. Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group. Circulation 1995; 92:1517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996; 348:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferreira E, Sunderji R, Gin K. Is oral sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacotherapy 1997; 17:1233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crystal E, Connolly SJ, Sleik K, et al. Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. Circulation 2002; 106:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerin NZ, Jacob S. The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis. Am J Med 2011; 124:875.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wharton JM, Piccini JP, Koren A, et al. Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation. J Am Heart Assoc 2022; 11:e020506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990; 65:74A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group. Eur Heart J 1989; 10:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weeke P, Delaney J, Mosley JD, et al. QT variability during initial exposure to sotalol: experience based on a large electronic medical record. Europace 2013; 15:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol 2003; 42:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makkar RR, Fromm BS, Steinman RT, et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 2003; 82:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locati EH, Zareba W, Moss AJ, et al. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation 1998; 97:2237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drici MD, Clément N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 2001; 24:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kehoe RF, Zheutlin TA, Dunnington CS, et al. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 1990; 65:58A.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 925 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/019865s021lbl.pdf.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3941198" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8202100" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10047618" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Sotalol: An important new antiarrhythmic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10684524" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Sotalol: Current Status and Expanding Indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090546" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Probing the interaction between inactivation gating and Dd-sotalol block of HERG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2170562" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8122604" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4017207" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2820614" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2153477" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1705386" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3518383" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6720518" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Clinical electrophysiology of intravenous sotalol, a beta-blocking drug with class III antiarrhythmic properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3706170" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Concentration-dependent pharmacologic properties of sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403731" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pharmacology, pharmacodynamics and pharmacokinetics of sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9265427" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9669266" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17100674" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Comparison of a standard versus accelerated dosing regimen for D,L-sotalol for the treatment of atrial and ventricular dysrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10684532" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11509917" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Importance of QT interval determination and renal function assessment during antiarrhythmic drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7900626" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10078083" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9645896" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7912296" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7817931" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34662471" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cardioversion of recent-onset atrial fibrillation using intravenous antiarrhythmics: A European perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27554842" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Efficacy of Intravenous and Oral Sotalol in Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27261833" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10874228" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8346727" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Usefulness of sotalol for life-threatening ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8332150" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9247523" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10369848" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1617780" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7664435" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Efficacy and safety of d-sotalol, a pure class III antiarrhythmic compound, in patients with symptomatic complex ventricular ectopy. Results of a multicenter, randomized, double-blind, placebo-controlled dose-finding study. The d-Sotalol PVC Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8691967" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9399605" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Is oral sotalol effective in converting atrial fibrillation to sinus rhythm?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12093773" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21854895" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The efficacy of sotalol in preventing postoperative atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35060388" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Comparative Safety and Effectiveness of Sotalol Versus Dronedarone After Catheter Ablation for Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2403737" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Clinical safety profile of sotalol in patients with arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2676535" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23787903" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : QT variability during initial exposure to sotalol: experience based on a large electronic medical record.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12849654" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8921798" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Sex difference in risk of torsade de pointes with d,l-sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8230644" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12861106" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9631873" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11480490" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2294689" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
